Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 66 of 107 for:    "21-hydroxylase deficiency"

Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS (SHK001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03905603
Recruitment Status : Recruiting
First Posted : April 5, 2019
Last Update Posted : October 16, 2019
Sponsor:
Information provided by (Responsible Party):
Su Hee Kim, University of Virginia

Brief Summary:
The objective of the study is to determine the relative contributions of four established predictors of hyperandrogenism (luteinizing hormone [LH] secretion, ovarian response to recombinant human chorionic gonadotropin [r-hCG] administration, adrenal response to adrenocorticotropic hormone [ACTH] administration, and hyperinsulinemia) in older vs. young women with Polycystic Ovary Syndrome (PCOS) in a cross-sectional, physiological study. The investigators hypothesize that hyperinsulinemia is a stronger independent predictor of free testosterone (T) in older reproductive aged (vs. young) women with PCOS.

Condition or disease Intervention/treatment Phase
Polycystic Ovary Syndrome Drug: ACTH Drug: rhCG Early Phase 1

Detailed Description:
PCOS is a highly prevalent reproductive disorder characterized by hyperandrogenism (HA) and oligo/anovulation. PCOS is also associated with metabolic syndrome, obesity and insulin resistance. In young women with PCOS, several factors contribute to HA: a) excess LH secretion, b) abnormal ovarian steroidogenesis, c) abnormal adrenal steroidogenesis, and d) hyperinsulinemia/ insulin resistance. Of interest, HA (and menstrual function) improves with age in PCOS. However, the relative contributions of the aforementioned HA-related factors in young adult vs. late reproductive-aged women with PCOS are not known. Identifying the most important predictor(s) of HA in older women with PCOS will be critically important for devising the most relevant therapeutic strategies for older women with PCOS. The investigators propose to determine the relative contributions of four established predictors of HA (LH secretion, ovarian response to r-hCG administration, adrenal response to ACTH administration, and hyperinsulinemia) in older vs. young women with PCOS in a physiological study. The investigators hypothesize that hyperinsulinemia is a stronger independent predictor of free testosterone (T) in older reproductive aged (vs. young) women with PCOS. In addition, the investigators hypothesize that, in older vs. young women with PCOS: a) ovarian response to r-hCG will be a weaker independent predictor of free T; b) mean LH will be a stronger independent predictor of free T; and c) the predictive ability of adrenal response to ACTH will be similar. This will be a cross-sectional physiological study. Ordinary Least Square (OLS) regression will be utilized to determine the relative contributions of 4 established predictors of HA in older vs. young women with PCOS. Statistical plans include intra-age group hypothesis testing, inter-age group hypothesis testing, and a ranking of the importance of predictors in each age group.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 144 participants
Intervention Model: Single Group Assignment
Intervention Model Description: This is a cross-sectional physiological observational study.
Masking: None (Open Label)
Masking Description: No masking is involved in this study.
Primary Purpose: Basic Science
Official Title: Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Actual Study Start Date : October 8, 2019
Estimated Primary Completion Date : April 2023
Estimated Study Completion Date : April 2024


Arm Intervention/treatment
Experimental: ACTH (Cosyntropin), rhCG (Ovidrel)
ACTH (Cosyntropin) administered 250 mcg IV; rhCG (Ovidrel) administered 250 mcg IV
Drug: ACTH
ACTH (Cosyntropin) 250 mcg will be given once during the study.
Other Name: Cosyntropin

Drug: rhCG
rhCG (Ovidrel) 250 mcg will be given once during the study.
Other Name: Ovidrel




Primary Outcome Measures :
  1. Change in calculated free testosterone concentrations [ Time Frame: baseline, 30 mininutes and 1 hour after adrenocorticotropic hormone (ACTH), 24 hours after recombinant human chorionic gonadotropin (rhCG). ]
    pg/mL

  2. Mean luteinizing hormone (LH) concentrations [ Time Frame: overnight frequent blood sampling (every 10 mininutes for 12 hours) ]
    IU/L

  3. Change in ovarian 17-hydroxyprogesterone to r-hCG [ Time Frame: baseline, and 24 hours after receiving rhCG ]
    ng/mL

  4. Change in adrenal 17-hydroxyprogesterone to ACTH [ Time Frame: baseline, 30 minutes, and 60 minutes after ACTH ]
    ng/mL

  5. Mean insulin level during oral glucose tolerance test [ Time Frame: during 2 hours of oral glucose tolerance test ]
    uIU/mL


Secondary Outcome Measures :
  1. Matsuda index [ Time Frame: during 2 hours of glucose tolerance test ]
    It is an index calculated by using glucose and insulin levels

  2. LH pulse frequency [ Time Frame: overnight frequent blood sampling (every 10 minutes for 12 hours) ]
    pulses/hour

  3. Change in dehydroepiandrosterone (DHEA) to r-hCG [ Time Frame: baseline, and 24 hours after r-hCG ]
    ng/mL

  4. Change in DHEA to ACTH [ Time Frame: baseline, 30 minutes and 1 hour after ACTH ]
    ng/mL

  5. Change in androstenedione to r-hCG [ Time Frame: baseline, and 24 hours after r-hCG ]
    ng/mL

  6. Change in androstenedione to ACTH [ Time Frame: baseline, 30 minutes and 1 hour after ACTH ]
    ng/mL



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 47 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   This is a study regarding PCOS, so only females will be eligible.
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Women with PCOS aged 20-30 years and 40-47 years. Subject is considered to have PCOS if she has current or verifiable history of: a) clinical and/or biochemical evidence of hyperandrogenism plus b) oligomenorrhea (average menstrual cycle length >45 days or fewer than 9 menses/year) or irregular menstruation (substantially inconsistent menstrual cycle length). Note: For subjects aged 40-47 years, they will be allowed to participate if they have fewer than 10 menses/year (average menstrual cycle length >35 days) as long as they have a compelling past history of oligomenorrhea or irregular menstruation.
  • Screening safety labs within normal reference ranges although mild abnormalities that are common in obesity and/or hyperandrogenism will not be grounds for exclusion (see exclusion criteria).
  • Subjects must be willing and able to provide written informed consent.
  • Willingness to strictly avoid pregnancy (using non-hormonal methods) during the time of the study
  • Willingness and ability to comply with scheduled visits and study procedures

Exclusion Criteria:

  • Postmenopausal status (i.e., absence of periods for previous year plus elevated follicle stimulating hormone [FSH] level)
  • Biochemical evidence for perimenopause as defined by an anti-Mullerian hormone <0.5 ng/mL. As an alternative, cycle day 3 FSH > 9 IU/L (with concomitant estradiol level >80 pg/mL), if this testing is available, will serve as evidence of perimenopause status. NOTE: If FSH >9 IU/L on screening (but it is not cycle day 3), FSH and estradiol will be repeated on cycle day 3.
  • History of hysterectomy and/or bilateral oophorectomy
  • BMI ≥ 40 kg/m2
  • Inability to comprehend what will be done during the study or why it will be done.
  • Being a study of older women with PCOS, children and men will be excluded.
  • Pregnancy or lactation within the past 6 months. Subjects with a positive pregnancy test will be informed of the result by the screening physician.
  • Prisoners.
  • History of (or clinical evidence for) Cushing's syndrome or adrenal insufficiency.
  • History of congenital adrenal hyperplasia or 17-hydroxyprogesterone (17-OHP) >200 ng/dL, which suggest the possibility of congenital adrenal hyperplasia. 17-OHP will be collected during follicular phase. NOTE: if a 17-OHP >200 ng/dL and is confirmed on repeat testing, an ACTH-stimulated 17-OHP <1000 ng/dL will be required for study participation.
  • Total testosterone >150 ng/dL, which suggests the possibility of virilizing neoplasm.
  • DHEA-S greater than 1.5 times the upper limit of normal range (mild elevations may be seen in PCOS, so elevations < 1.5 times the upper limit of normal will be accepted in these groups).
  • Virilization
  • Diagnosis of diabetes mellitus (DM), fasting glucose ≥ 126 mg/dL, or a hemoglobin A1c of ≥ 6.5%.
  • Abnormal thyroid stimulating hormone (TSH). Subjects with stable and adequately-treated hypothyroidism, reflected by normal TSH values, will not be excluded.
  • Moderate to severe hyperprolactinemia. Mild prolactin elevations may be seen in PCOS, and elevations < 1.5 times the upper limit of normal will be accepted in this group.
  • Persistent liver abnormalities, with the exception that mild bilirubin elevations will be accepted in the setting of known Gilbert's syndrome. Mild transaminase elevations may be seen in women with obesity, so elevations <1.5 times the upper limit of normal will be accepted in this group.
  • Hemoglobin level is less than 11 g/dL.
  • Persistent hematocrit <36% and hemoglobin <12 g/dL.
  • Subjects who remain anemic after two sequential months of ferrous gluconate (325 mg twice daily) will be excluded from study participation.
  • Abnormal sodium, potassium, or bicarbonate concentrations or elevated creatinine concentration.
  • Significant history of pulmonary dysfunction (e.g., asthma or COPD requiring intermittent systemic corticosteroid, pulmonary hypertension, etc.).
  • History of known or suspected congestive heart failure.
  • History of known or suspected ischemic heart disease or cerebrovascular disease.
  • History of moderate to severe hypertriglyceridemia (triglyceride level > 500 mg/dL). Subjects with stable and adequately treated hypertriglyceridemia reflected by normal triglyceride values will not be excluded.
  • History of breast, ovarian, or endometrial cancer.
  • The cut off threshold for estimated dominant ovarian cyst size on the day of r-hCG injection will be 18 mm. Since the ultrasound will be assessed 3-4 days prior to r-hCG administration, we will estimate the size of the dominant follicle (at the time of r-hCG administration) using the typical rate of ovarian follicle growth of 1.4 mm per day.
  • Ovarian enlargement, defined by ovarian volume greater than 15 mm on transvaginal ultrasound
  • History of venous thromboembolism (e.g. deep venous thrombosis (DVT), pulmonary embolism (PE)).
  • History of blood clotting disorders (e.g., protein C, protein S, positive antiphospholipid antibodies).
  • First-degree relative history of blood clotting disorder, unless the same disorder has been formally excluded for the study subject. Note: any abnormal labs may be repeated to exclude a lab error.
  • No medications known to affect the reproductive system can be taken in the 2 months prior to screening and 3 months prior to the study. Such medications include oral contraceptive pills, metformin, progestins, glucocorticoids, anti-psychotics and/or mood stabilizers that are known to cause hormone abnormalities.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03905603


Contacts
Layout table for location contacts
Contact: Melissa G Gilrain, BS 434-243-6911 pcos@virginia.edu

Locations
Layout table for location information
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22901
Contact: Melissa Gilrain, BS    434-243-6911    pcos@virginia.edu   
Contact: Su H Kim, MD    434-243-6911    shk7x@virginia.edu   
Principal Investigator: Su H Kim, MD         
Sponsors and Collaborators
University of Virginia
Investigators
Layout table for investigator information
Principal Investigator: Su H Kim, MD University of Virginia

Layout table for additonal information
Responsible Party: Su Hee Kim, Dr., M.D., Assistant Professor, University of Virginia
ClinicalTrials.gov Identifier: NCT03905603     History of Changes
Other Study ID Numbers: 21723
First Posted: April 5, 2019    Key Record Dates
Last Update Posted: October 16, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Su Hee Kim, University of Virginia:
Polycystic Ovary Syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Adrenogenital Syndrome
Polycystic Ovary Syndrome
Hyperandrogenism
Ovarian Cysts
Cysts
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
46, XX Disorders of Sex Development
Disorders of Sex Development
Urogenital Abnormalities
Congenital Abnormalities
Chorionic Gonadotropin
Cosyntropin
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Reproductive Control Agents